,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-03-26 05:04:00,More doors are closing than opening for Pfizer (NYSE: PFE) with regard to the big drugmaker's options for its consumer healthcare business.,0.07134071737527847,0.04233729839324951,0.886322021484375,neutral,0.02900341898202896
1,2018-03-26 05:04:00,"Pfizer announced in October that it was reviewing strategic alternatives for the unit, including the potential for a sale, a spinoff, or keeping the business.",0.055336181074380875,0.011625894345343113,0.9330379366874695,neutral,0.043710287660360336
2,2018-03-26 05:04:00,Selling the unit appeared to be Pfizer's preferred option.,0.01904265582561493,0.017157824710011482,0.9637994766235352,neutral,0.001884831115603447
3,2018-03-26 05:04:00,The company moved forward with an auction in the hopes of generating up to $20 billion in a sale.,0.7822896242141724,0.015273929573595524,0.2024364471435547,positive,0.7670156955718994
4,2018-03-26 05:04:00,"However, the front-runner for buying Pfizer's consumer healthcare business, GlaxoSmithKline (NYSE: GSK) , dropped out of the bidding on March 23.",0.0211590938270092,0.8366789221763611,0.14216195046901703,negative,-0.8155198097229004
5,2018-03-26 05:04:00,Is a spinoff of the unit now Pfizer's best option?,0.0379287414252758,0.013811318203806877,0.9482599496841431,neutral,0.024117423221468925
6,2018-03-26 05:04:00,"In 2006, Pfizer sold its consumer healthcare business to Johnson & Johnson (NYSE: JNJ) for $16.6 billion.",0.020609555765986443,0.010451489128172398,0.9689388871192932,neutral,0.010158066637814045
7,2018-03-26 05:04:00,"That sale included products such as Benadryl, Listerine, Neosporin, and Sudafed.",0.0633685514330864,0.005712310783565044,0.9309191107749939,neutral,0.057656239718198776
8,2018-03-26 05:04:00,"A few years later, though, Pfizer rebuilt its consumer healthcare business with its acquisition of Wyeth.",0.8155475854873657,0.014408791437745094,0.17004364728927612,positive,0.8011388182640076
9,2018-03-26 05:04:00,"When Pfizer announced it was looking at another potential sale, Johnson & Johnson was naturally considered to be on the short list of top prospective buyers.",0.2633379101753235,0.012132726609706879,0.7245293259620667,neutral,0.251205176115036
10,2018-03-26 05:04:00,"However, in January J&J decided against attempting to buy Pfizer's consumer healthcare business.",0.042678479105234146,0.20931126177310944,0.7480102181434631,neutral,-0.1666327863931656
11,2018-03-26 05:04:00,One potential factor in the company's decision was the challenges of overcoming regulators' likely antitrust concerns.,0.6600427627563477,0.014851025305688381,0.32510626316070557,positive,0.6451917290687561
12,2018-03-26 05:04:00,Reckitt Benckiser withdrew from bidding on Pfizer's consumer unit only days before GlaxoSmithKline.,0.025198232382535934,0.6899251341819763,0.2848767042160034,negative,-0.6647269129753113
13,2018-03-26 05:04:00,The British drugmaker stated that it had offered to buy part of Pfizer's consumer business but not all of it.,0.15868662297725677,0.008838772773742676,0.8324746489524841,neutral,0.1498478502035141
14,2018-03-26 05:04:00,"Pfizer wasn't agreeable to only selling off part of the business, so another potential buyer was crossed off the list.",0.032645415514707565,0.6449257135391235,0.3224288821220398,negative,-0.6122803092002869
15,2018-03-26 05:04:00,Reckitt's exit left GlaxoSmithKline as the most likely candidate to win Pfizer's consumer unit.,0.18079963326454163,0.1905442625284195,0.6286560893058777,neutral,-0.009744629263877869
16,2018-03-26 05:04:00,"However, GSK CEO Emma Walmsley's statement that potential deals ""must meet our criteria for returns and not compromise our priorities for capital allocation"" hints that the price tag was too high for the company.",0.048000138252973557,0.8683897852897644,0.08361008018255234,negative,-0.8203896284103394
17,2018-03-26 05:04:00,"In Pfizer's Q3 conference call , CEO Ian Read stated that he expected ""broad interest from potential acquirers.""",0.8270281553268433,0.012000927701592445,0.16097092628479004,positive,0.8150272369384766
18,2018-03-26 05:04:00,"But with J&J, GlaxoSmithKline, and Reckitt Benckiser out of the running, who's left?",0.020684361457824707,0.09458891302347183,0.8847267031669617,neutral,-0.07390455156564713
19,2018-03-26 05:04:00,Nestle is one name that's been mentioned.,0.029070939868688583,0.015805507078766823,0.9551236033439636,neutral,0.01326543278992176
20,2018-03-26 05:04:00,"While Nestle is known primarily as a food company, it has taken steps in recent years to expand into healthcare.",0.6839815378189087,0.009512493386864662,0.3065059185028076,positive,0.6744690537452698
21,2018-03-26 05:04:00,The company's Nestle Health Sciences subsidiary develops nutritional products and has invested in other pure-play healthcare organizations.,0.14842838048934937,0.004954146686941385,0.8466175198554993,neutral,0.14347423613071442
22,2018-03-26 05:04:00,"In addition, Nestle CEO Mark Schneider's background is in healthcare.",0.02302470989525318,0.006900555454194546,0.9700747728347778,neutral,0.01612415537238121
23,2018-03-26 05:04:00,Schneider served as CEO of Fresenius before taking the helm at Nestle.,0.031101291999220848,0.016141951084136963,0.9527567625045776,neutral,0.014959340915083885
24,2018-03-26 05:04:00,Procter & Gamble (NYSE: PG) is another prospective acquirer.,0.06049199029803276,0.00526514882221818,0.9342429041862488,neutral,0.05522684007883072
25,2018-03-26 05:04:00,"Pfizer's products, including Advil, Centrum, Nexium, and Robitussin, appear to be solid additions to P&G's current consumer healthcare lineup, which include Metamucil, Nyquil, Pepto-Bismol, and Prilosec.",0.91499924659729,0.013859645463526249,0.0711410716176033,positive,0.9011396169662476
26,2018-03-26 05:04:00,One other possibility is Abbott Labs (NYSE: ABT) .,0.017630552873015404,0.011969742365181446,0.9703997373580933,neutral,0.005660810507833958
27,2018-03-26 05:04:00,"Abbott's current primary consumer focus is on nutritional products, and Pfizer's consumer healthcare products would bring a different flavor to Abbott's offerings.",0.04794527590274811,0.008886730298399925,0.943168044090271,neutral,0.03905854374170303
28,2018-03-26 05:04:00,And there's still another option for Pfizer -- turning to private equity funds.,0.06001172959804535,0.010584340430796146,0.9294039011001587,neutral,0.04942739009857178
29,2018-03-26 05:04:00,"Although most of the buzz has centered on big names like J&J, GlaxoSmithKline, and others, private equity could very well be on the table.",0.07342592626810074,0.02935601957142353,0.8972179889678955,neutral,0.04406990855932236
30,2018-03-26 05:04:00,"However, it's entirely possible that Pfizer simply won't get the price it wants for the consumer business.",0.025969937443733215,0.7228878140449524,0.2511422038078308,negative,-0.6969178915023804
31,2018-03-26 05:04:00,I suspect that's what we're seeing with the GlaxoSmithKline exit.,0.0396103635430336,0.01320212334394455,0.9471874833106995,neutral,0.02640824019908905
32,2018-03-26 05:04:00,Spinning off the consumer healthcare unit could be the best alternative for Pfizer shareholders.,0.03132220357656479,0.04948076605796814,0.9191970825195312,neutral,-0.01815856248140335
33,2018-03-26 05:04:00,Pfizer CFO Frank D'Amelio stated a few months ago that this was exactly what happened with the company's animal health business.,0.014409871771931648,0.03630327060818672,0.9492868781089783,neutral,-0.021893398836255074
34,2018-03-26 05:04:00,"He noted that Pfizer received offers it considered to be too low and opted to spin off the business as a separate entity, called Zoetis , rather than sell it for a lower price.",0.037993304431438446,0.5522800087928772,0.40972670912742615,negative,-0.5142866969108582
35,2018-03-26 05:04:00,That has turned out to be a smart move.,0.8385087847709656,0.022234102711081505,0.13925711810588837,positive,0.8162747025489807
36,2018-03-26 05:04:00,Zoetis stock is up more than 150% since the spinoff in 2013.,0.9464653730392456,0.01819753646850586,0.035337064415216446,positive,0.9282678365707397
37,2018-03-26 05:04:00,"During the same period, Pfizer's share price has increased only 25%.",0.9082661271095276,0.023662442341446877,0.0680713802576065,positive,0.8846036791801453
38,2018-03-26 05:04:00,"There's no guarantee, however, that a spinoff of the consumer healthcare business would be as successful as the Zoetis spinoff.",0.753167450428009,0.012179089710116386,0.23465345799922943,positive,0.7409883737564087
39,2018-03-26 05:04:00,It's a totally different ballgame to market consumer products than to sell primarily to veterinarians and livestock producers.,0.027366645634174347,0.00922727957367897,0.9634060859680176,neutral,0.018139366060495377
40,2018-03-26 05:04:00,"The option no one wants

Of course, there is one other alternative for Pfizer -- keeping the consumer healthcare business.",0.024247199296951294,0.016872581094503403,0.9588801860809326,neutral,0.007374618202447891
41,2018-03-26 05:04:00,I think it's fair to say that it's the one option no one wants.,0.09338092058897018,0.035318758338689804,0.8713003396987915,neutral,0.05806216225028038
42,2018-03-26 05:04:00,Pfizer hasn't really wanted to be in the consumer healthcare business for years.,0.013980435207486153,0.013922849670052528,0.9720968008041382,neutral,5.758553743362427e-05
43,2018-03-26 05:04:00,That's why the company sold its consumer unit to J&J more than a decade ago.,0.027498191222548485,0.0074628135189414024,0.9650389552116394,neutral,0.020035378634929657
44,2018-03-26 05:04:00,Shareholders would see it as a negative if Pfizer retained the business after announcing that it was evaluating strategic alternatives.,0.0349879115819931,0.5380220413208008,0.4269900619983673,negative,-0.5030341148376465
45,2018-03-26 05:04:00,My view is that Pfizer really would rather sell the consumer unit than spin it off.,0.01410315278917551,0.035227179527282715,0.9506696462631226,neutral,-0.02112402766942978
46,2018-03-26 05:04:00,But the company might not be able to get the $20 billion it wants.,0.08990488201379776,0.5694220066070557,0.3406731188297272,negative,-0.4795171320438385
47,2018-03-26 05:04:00,Would Pfizer settle for less -- perhaps $18 billion?,0.04492834210395813,0.030130300670862198,0.9249414205551147,neutral,0.014798041433095932
48,2018-03-26 05:04:00,We'll find out soon enough.,0.11239821463823318,0.010297414846718311,0.8773043751716614,neutral,0.10210079699754715
49,2018-03-26 05:04:00,It's now past the deadline for bids from potential acquirers.,0.3105546236038208,0.12038317322731018,0.5690621733665466,neutral,0.19017145037651062
50,2018-03-26 05:04:00,Pfizer will make a decision this year.,0.04324112460017204,0.009906316176056862,0.9468525648117065,neutral,0.03333480656147003
51,2018-03-26 05:04:00,"If a sale isn't announced within the next few months, a spinoff could be the next best thing.",0.06377595663070679,0.02091275528073311,0.9153112769126892,neutral,0.04286320134997368
52,2018-03-26 05:04:00,"10 stocks we like better than Pfizer

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.11657272279262543,0.02325672097504139,0.8601706027984619,neutral,0.09331600368022919
53,2018-03-26 05:04:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
54,2018-03-26 05:04:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them!",0.20318953692913055,0.013583369553089142,0.7832270860671997,neutral,0.18960615992546082
55,2018-03-26 05:04:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
56,2018-03-26 05:04:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
57,2018-03-26 05:04:00,Keith Speights owns shares of Pfizer.,0.01755751296877861,0.012881859205663204,0.9695606827735901,neutral,0.004675653763115406
58,2018-03-26 05:04:00,The Motley Fool owns shares of and recommends Johnson & Johnson.,0.03412320837378502,0.015267993323504925,0.9506087303161621,neutral,0.01885521411895752
59,2018-03-26 05:04:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
60,2018-03-26 05:04:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
